09:59 AM EDT, 09/04/2024 (MT Newswires) -- Collegium Pharmaceutical ( COLL ) said Wednesday that it has completed its $525 million, all-cash acquisition of Ironshore Therapeutics, which markets and distributes the Jornay PM drug treatment for attention deficit hyperactivity disorder.

Collegium said it now expects to generate between $620 million to $635 million in product revenue this year, up from its prior forecast of $580 million to $595 million.

The company also said it now expects 2024 adjusted earnings before interest, taxes, depreciation and amortization of $395 million to $405 million, up from $380 million to $395 million anticipated previously.

Price: 37.42, Change: -0.01, Percent Change: -0.01